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study question: What are the opinions of professionals in the field of genetics, reproductive science and metabolic diseases on the
development of mitochondrial replacement technologies to be used in the context of medically assisted reproduction?
summary answer: Although concerns regarding safety remain, interviewees supported the development of nuclear transfer techniques
to help women who are at risk of transferring a mitochondrial DNA disease to their offspring conceive a genetically related child.
what is known already: Technological developments in the field of nuclear transfer have sparked new interest in the debate on the
acceptability of the use of donor oocytes to prevent the transmission of mitochondrial diseases. For example, in the UK, extensive public con-
sultations have been done to investigate whether such techniques would allow the passing of a law that involves making changes to a human
oocyte or embryo before transfer to a woman’s body. Until now, continental European countries seem to await the outcome of the British
debate before themselves considering the arguments for and against this technology.
study design, size, and duration: We interviewed 12 professionals from Belgium and The Netherlands.
participants/materials, setting, and methods: We conducted 12 interviews with fertility specialists, scientists, clinical
geneticists, a pediatrician specialized in metabolic diseases and a specialist in metabolic diseases. The profiles of the interviewees varied but all had
experience with mitochondrial diseases, either in treating patients or in providing counseling to patients or to prospective parents. The interviews
were conducted face-to-face and took 30–45 min. The language of the interviews was Dutch. We analyzed the transcript of these interviews using
QSR NVIVO 10 software to extract themes and categories.
main results and the role of chance: This study has shown that, although amongst the professionals we interviewed therewas
support for the development and deployment of nuclear transfer, this support does not necessarily correspond to uniform opinions about the
importance of having a genetically own child or the contribution of mitochondrial DNA to essential characteristics of an individual.
limitations, reasons for caution: In translating the quotes from Dutch to English some of the linguistic nuances may have been
lost. We only interviewed 12 individuals, in two countries, whose view may not be representative of existing values and opinions that may be held
by professionals worldwide on this matter. To further explore the issue at hand, a subsequent investigation of the opinions of people affected by
mitochondrial diseases and of the general public is necessary.
wider implications of the findings: With this study we have demonstrated there is in principle support for the nuclear transfer
technique from Dutch and Belgian professionals. Further research, both scientific and ethical, is needed to define the modalities of its possible
introduction in the fertility clinic.
study funding/competing interest(s): This research was funded by GROW, School for Oncology and Developmental
Biology, The Netherlands. The authors declare no conflict of interest.
trial registration number: N/A.
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Introduction
Mitochondrial DNA (mtDNA) has specific characteristics distinct from
nuclear DNA, in that it is only transferred maternally and its transmission
is unpredictable. Hence, mutations in mtDNA may be transferred in
various degrees, and the severity of the phenotype is often dependent
on the mutant load. At present no cure exists for diseases associated
with mutations in the mtDNA (Smeets, 2013).
Current options for some of thewomen who carrya disease related to
a mutation in the mtDNA and who desire to reproduce with their own
genetic material without transmitting the disease are PGD and prenatal
diagnosis. PGD has been demonstrated in a few cases (e.g. NARP, neur-
opathy, ataxia, and retinitis pigmentosa, a mitochondrial disease affecting
chiefly the nervous system, Steffann et al., 2006) and MELAS (mitochon-
drial encephalomyopathy, lactic acidosis, and stroke-like episodes, a
mitochondrial disease affecting chiefly the brain, nervous system and
muscles, Heindryckx et al., 2014), and, unlike PGD for mutations in
the nuclear genes, consists of picking the embryo with a mutant load
below a certain threshold. However, this is not a solution for homoplas-
mic women, or for those with a very high mutation load, as these women
would always transfer a high mutant load to their offspring. Even in the
case of heteroplasmic transmittance the technique has its drawbacks
as it has been suggested that heteroplasmy may be variable between
cells, and hence the biopsied blastomere may not be representative of
the embryo (Sallevelt et al., 2013). Also prenatal diagnosis, such as am-
niocentesis, has its drawbacks as it implies an investigation of cells from
a subset of tissues, and the mutant load may differ between tissues
(Smeets, 2013). The only option at the moment for couples who want
to avoid the transfer of a mitochondrial disease to their children is to
opt for oocyte donation, but this implies that the mother is unable to
pass on her own genetic material to her child. A potential future route
which would avoid the pitfalls present in PGD or prenatal diagnosis for
mitochondrial diseases and which would allow a carrier woman to use
her own nuclear genetic material for procreation is mtDNA replacement
through nuclear transfer. This would allow women who are homoplas-
mic or who have a high mutant load and those who want to avoid all re-
sidual risk to have their genetically own children. Currently, at least two
techniques are under development (HFEA, 2014). One technique con-
sists of the transfer of the spindle of chromosomes from an oocyte of the
woman wishing to conceive to a donor oocyte, before fertilization
(Tachibana et al., 2009; Paull et al., 2013). The other technique involves
the transfer of the pronuclei of a fertilized oocyte (zygote) of the woman
wishing to conceive to an enucleated donor oocyte (Craven et al., 2010).
Other possible techniques include polar body transfer (Wang et al.,
2014), which is suggested to imply less risk of mtDNA carryover than
transfer of the pronuclei, or the transfer of the nucleus of a blastomere
of an embryo, which may lead to reproductive cloning.
The possibility to use germ-line therapy to cure mitochondrial disease
has been discussed already since the 1990s (Rubenstein et al., 1995; De
Wert, 2000; Gezondheidsraad, 2001). More recently, technological
developments have sparked new interest in the debate, especially in
the UK. In documents from the Human Fertilisation and Embryology
Authority (HFEA) and The Nuffield Council on Bioethics specific
ethical issues that arise with this technology were discussed (Nuffield
Council on Bioethics, 2012; HFEA, 2013). A major issue in this debate
is the question at which point the technique was considered safe
enough to be introduced in the clinic. A related issue concerns the
necessity and extent of follow-up of children and perhaps also of
further generations. Further, questions regarding the fact that this
would imply germ-line modification were raised, as it would mean modi-
fying the genome that a person can transmit to her child and the child’s
entire lineage. Another topic of debate was the status of the mtDNA
donor and her relation to the future child. Does the donation of cyto-
plasm introduce a third parent? Do donors have the right to receive in-
formation about resulting children and do donor children have the
right to receive information about the mtDNA donor? How does the
fact that these children are created and conceived using the DNA of
three parties, in experimental circumstances, affect their sense of iden-
tity, if at all? And, given that this technique would only apply to the
context of a limited number of people, does this allow for the spending
of research money and should the resulting treatment be part of public
health coverage?
Until now, continental European countries seem to await the outcome
of the British debate before themselves considering the arguments for
and against this technology (on 3 and 24 February 2015, while this
paper was in press, both houses of Parliament in the UK voted in favor
of new rules allowing the HFEA to grant licenses for experimental use
of mitochondrial replacement technologies in humans. Clinics can
apply for such licenses as from the autumn of 2015 (Devlin, 2015)).
However, there are several reasons for making this an international
debate. Firstly, also in other countries prospective parents facing the
risk of transmitting a mitochondrial disorder have an interest in the devel-
opment of effective and safe technologies that may help them to have
healthy children. Secondly, many of the concerns raised by the prospect
of using mitochondrial replacement technologies to help those couples
are of an ethical rather than merely technical nature. This means that
whatever the outcome of the British debate, the weighing of relevant
considerations may lead to different conclusions in other societal and cul-
tural contexts. Thirdly, as the use of these technologies may be regarded
as a ‘crossing of the Rubicon’ with regard to germ-line gene therapy, this
is an issue of more than national interest that requires a proactive inter-
national debate.
As a contribution to this wider debate we present the outcomes of a
study of the views and opinions of Belgian and Dutch scientists and pro-
fessionals on the development of mitochondrial replacement technolo-
gies to be used in the context of medically assisted reproduction.
Although close neighbors geographically, Belgium and the Netherlands
are very different countries with regard to general attitudes to medically
assisted reproduction and embryo research. Very much like the UK,
Belgium has a strong tradition of innovation in this field, combined with
a liberal legislation that does not impose many limits upon the use of re-
productive technologies. Under certain conditions the Belgian Embryo
Act allows the creation of embryos for research. It also allows manipula-
tions of reproductive material that would amount to germ-line gene
therapy, unless these procedures would fall under the interdiction of pro-
cedures with ‘eugenic’ intent. Hence, there is no legal barrier to taking the
step to clinical experiments with this technology in Belgium. The Nether-
lands, by contrast, does not have a strong tradition of research in this field
and the cultural and political climatewith regard toassisted reproduction is
generally more conservative. For example, the Dutch Embryo Act forbids
the creation of embryos for research (HC 2001). Unlike both the UK and
Belgium, the Netherlands is one of the cosignatories of the 1997 Oviedo
Convention (Declaration on Human Rights and Biomedicine) of the
Council of Europe, article 13 of which includes a general prohibition of
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germ-line gene modification. However, the Netherlands has made a
provision allowing her upon ratification to restrict this ban only to modifi-
cation of the nuclear DNA. This was done in order to keep options
open precisely with regard to mitochondrial replacement technologies
(Gezondheidsraad, 2001; Dondorp and Bolhuis, 2002). But as pointed
out by the Health Council of the Netherlands, the legal provision forbid-
ding the creation of embryos for research still stands in the way of effect-
ively developing technologies that would involve creating embryos to be
used in preclinical safety studies.
By selecting interviewees from countries with a different legal context
and tradition in embryo research we expected to find different ethical
opinions on the desirability to create and use embryos for this research.
We also expected to find a strong opposition toward the use of the
term tri-parent baby. We found, however, that the use of embryos for
this type of research was in general condoned, and that the attitude
toward the mtDNA donor was related to how participants viewed the
status of mtDNA.
Methodology
As this is the first study in Belgium and the Netherlands querying stakeholder
views with regard to the acceptability of the use of nuclear transfer to allow
carrier women to have unaffected offspring using their own oocytes, we
chose a qualitative research method. We interviewed 12 professionals to
perform an exploratory analysis and overview of important concepts and
themes. We selected an initial list of respondents involved with genetics
and reproduction in the context of mitochondrial diseases. This resulted in
six interviews. Another six participants were contacted based on suggestions
by the participants. Interview transcription and data analysis was started by
K.H. at the same time as the data collection. After the 12th interview no
new themes were discovered, meaning that saturation was obtained. The
interviews took place between March and September 2014. The profiles
of the interviewees varied but all had experiencewith mitochondrial diseases,
either in treating patients or in providing counseling to patients or to pro-
spective parents (Table I). The interviews were conducted face-to-face
and took 30–45 min. The language of the interviews was Dutch.
The themes in the interview guide were inspired by the discussions and the
consultations of the HFEA (HFEA, 2013), the Nuffield Council of Bioethics
(Nuffield Council on Bioethics, 2012) and the report of the Dutch Health
Council (Gezondheidsraad, 2001). The first part of the interview focused
on the two major techniques (spindle transfer and pronuclei) and contained
open-ended questions on acceptable risk (physical and psychosocial), neces-
sity and acceptability of embryo research, a comparison with the alternatives
(PGD/preimplantation genetic screening/oocyte donation), need for
follow-up of the resulting children and the importance of genetically
related children. The second part dealt with topical ethical issues, such as
the status of the mtDNA donor, the acceptability of germ-line modification,
the difference between mitochondrial and nuclear DNA and the question
whether this research should be funded and any resulting treatment should
be part of publicly funded health care. A semi-structured interview scheme
was used, as this allows for the investigation of similar themes across the sub-
jects while facilitating the exploration of individual values of the interviewees
in depth and facilitating further exploration of additional themes that would
come up during the interview (Sankar and Jones, 2008). K.H. was the inter-
viewer in all cases.
Audiotapes of the sessions were transcribed verbatim. QSR Nvivo 10
(supplied by the Maastricht University) was used to code the transcripts.
First, an open coding was performed to break down the data into different
concepts. In a second pass, these concepts were rearranged according to
different tree structures. Ultimately, codes were combined into core
categories. G.d.W. and W.D. read through the transcripts and suggested
additional themes. Quotes were selected to highlight the themes and were
translated into English. We have not provided the profession or affiliation
of the intervieweewith specific quotes as we have guaranteed them complete
anonymity. We also use the pronoun ‘she’ when referring to the interviewee
regardless of gender for the same reason.
Results
The importance of a genetically own child
All interviewees stated that the use of IVF with (entire) donor oocytes is a
safe and tested solution to help couples at risk of having a child with a
mitochondrial disease to procreate. Hence, for the participants, the
rationale behind the development of nuclear transfer techniques to
prevent transmission of these diseases is that having a genetically own
child is of sufficient importance to prospective parents. Some intervie-
wees stated that many people desiring to procreate would go to extremes
to have their genetically own child and hence be ready to embark on a
trajectory involving experimental techniques. According to some of
the participants, the desire to have a genetically own child is evolutionary
and hardwired, as is explicit in the following quote: ‘It is a very compli-
cated situation, it is evolution-based and hardwired in our brain that
we want a genetically own child, although you could ask how important
that really is’. The use of the word really in this quote demonstrates that
this participant thinks that, although evolution-based, this desire may be
overcome. Another respondent indeed suggested that more investiga-
tion was needed as to why people would desire a genetically own child
so much. One interviewee stressed that she thought that the reluctance
to opt for using donor oocytes as a possible alternative form of assisted
reproduction was because of the practical difficulties:
Donating oocytes is a difficult procedure, few do it out of altruistic motives.
So I think, what I want to say is in fact, the willingness to opt for oocyte
donation will increase if oocyte banks become more readily available, if
you do not have to find a donor yourself, if there is some matching with
regard to color of the eyes and hair and other stuff that is possible with
sperm banks. (BE)
This respondent was clearly of the opinion that the reason why many
people do not choose oocyte donation as an alternative for assisted
reproductive technology procedures that would allow them to have
their genetically own child was at least partially due to difficulties that
could be overcome by compensating oocyte donors. Although oocyte
........................................................................................
Table I Information about the interviewees in a study of
professionals on the use of mitochondrial replacement to
avoid transfer of mitochondrial diseases.
#




Specialist in metabolic diseases 1
Location of interviewees The Netherlands 6
Belgium 6
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donation is necessaryalso for nuclear transfer, this interviewee suggested
that once donation of the (entire) oocyte becomes standard practice as
a fertility treatment, less importance will be attached to having a child of
which both parents are genetic partners and the extra step of replacing
the nucleus may no longer be considered necessary.
Although all interviewees accepted this new technique to allow people
to have their genetically own child, several interviewees suggested that
the fact that research groups were pursuing this type of research was pri-
marily because of the prestige it would generate, to be among the first to
develop a technique with treatment potential that would imply manipu-
lation of a human embryo, rather than the fact that this was a technique
that would help many. As an alternative to helping people conceive a gen-
etically related child free of the disease, one interviewee stated that ‘an
option would be to try to improve treatment of mitochondrial diseases
as an alternative to manipulating the genetic material.’ A subset of parti-
cipants pointed out that the information research on nuclear transfer
would yield regarding the functioning of the cell, also perhaps for older
women trying to conceive, would partly justify the research into this spe-
cific type of manipulation of the embryo. As to the question whether the
possible resulting fertility treatment would have to be part of public
health care coverage, most participants agreed that this would have to
be decided based on the priority with regard to other treatments.
One interviewee stated that
This is clinical care. If you can in a reliable way use nuclear transfer to beget
healthy children who would otherwise have a mitochondrial disease, I would
say that this is care (emphasis mine). The same goes for preimplantation
genetic diagnosis. (NL)
So to help people at high risk of transmitting serious disease to have their
genetically own children should, according to this interviewee, be part of
standard (and reimbursed) care.
Another interviewee, however, stated that:
I think that we are sometimes stretching it a bit, it is already so with preimplan-
tation genetic diagnosis, it is to some extent an enormous luxury problem. I
understand that infertility, you want to do something about it, and it can be ex-
tremely burdensome. But if we were to look on a global scale how we are to
divide the costs of health care. . .one could voice one’s doubts about it. (BE)
So this interviewee, although not as such opposing research and reim-
bursement of these techniques still questioned whether the distribution
of health care money would not be better directed toward other more
urgent aims.
The contribution of the mtDNA
In our study we found opposite views on the contribution of mitochon-
drial DNA. Those participants who considered mtDNA a less important
form of DNA also considered it irrelevant to the identity of the resulting
child. For example, one interviewee stated that:
Yes, nuclear DNA defines your characteristics if you think genetics is import-
ant. You could say that if you are going to do genetic manipulation on nuclear
DNA that the results are passed on from generation to generation and that it
affects the individual. Those mitochondria they are also passed on but we
assume that a mitochondrion is a very stupid thing with only a limited
amount of DNA that just has to maintain a motor and does not define the
characteristics of an individual. For me, this is also a moral difference. (BE)
So this interviewee explicitly links the status of mitochondria as non-
identity defining to the moral acceptability of techniques that would in
principle change the germ line. Other participants, however, did not
believe mtDNA was less identity defining as nuclear DNA, as mutations
in mtDNA would lead to serious diseases as well, a fact that is as such
identity affecting. One interviewee suggested that if the avoidance of
disease is the primary concern, this would imply that also techniques
to prevent diseases that consist of germ-line nuclear genetic modification
would be acceptable. For this interviewee, what was morally acceptable
in terms of DNA intervention was based on whether a certain mutation
would lead to a diseases (rather than to a variation of a non-medical char-
acteristic), not whether it was situated in the mitochondrial or nuclear
DNA.
It follows logically that those who believed that mtDNA was less iden-
tity defining than nuclear DNA thought that the term three-parent child
as it is used in the media worldwide is exaggerated, as the characteristics
of the resulting child that the mtDNA donor contributes was deemed by
them too limited. As such, these respondents were strong proponents
of donor anonymity also in this context. However, some of those who
believed that mitochondria may also contribute substantially to the
identity-defining characteristics of the resulting individual did think that
the term three-parent child was not completely exaggerated:
A child with three parents? Yes you cannot deny that. Unless you state that
well that little bit of cytoplasm shouldn’t have a name, it is the same as a dress
or. . .But it is DNA, it is crucial, without it you do not have a human being. It is
not a dress, I believe it is even more than a surrogate mother. (NL)
This interviewee subsequently stated that because of the fact that three
people contributed to the resulting child, careful counseling of the family
regarding how to deal with this situation also after conception and even
till the child reaches puberty was needed, as this was typically the time
when children started to question their origins. Related, a subset of inter-
viewees was not convinced that the role of the mtDNA donor was trivial,
and they made the analogy with donors of entire gametes, where the
status of the donor with respect to the resulting child is not yet settled,
and with the complex structure of present-day family formation which
is moving away from the nuclear family.
Safety as an ethical requirement
All interviewees thought that the nuclear transfer technique was in prin-
ciple a good technique to prevent the passing on of a disease of the
mtDNA. There was some consensus that the nuclear transfer techni-
ques will not fully replace PGD but will either be offered as a second
line possibility after PGD is unsuccessful or to those for whom PGD or
prenatal diagnosis is not an option, due to homoplasmy or high mutation
load:
If people have a high risk to have an abnormal embryo then you would manipu-
late, but if this risk is relatively low, but you still want to eliminate those
embryos, then you would probably opt for selection. So yes I think you
need to juxtapose those options and choose on the basis of the problem. (NL)
However, the main concern of all participants was that the technique
would not be safe. If asked which technique she would prefer one re-
spondent stated that ‘I would prefer the one with the highest efficiency
and safety, and then preferably also the most feasible and accessible
one’. This quote suggests that first and foremost technical and economic
issues influence the decision whether this technique is an acceptable
option, rather than other ethical issues. All interviewees agreed that in
order for these techniques to be used efficiently and safely, more









aastricht user on 21 Septem
ber 2021
research was needed, both in the form of animal research as well as in the
form of preclinical safety research using human embryos. Some explicitly
named the cytoplasm transfer which was occasionally done in the 1990s
to help older women conceive as a paradigmatic example of why new
techniques should not be hastily introduced, as this technique was con-
sidered unsafe in view of a higher than expected number of abnormal
pregnancies and births.
Participants also all agreed that nuclear transfer is similar to other new
fertility technologies in that safety can only be assessed after the first
children have been born, and possibly even after the children of these
children were born. As one of our interviewees stated, for such techni-
ques ‘the proof of the pudding is in the eating’. All agreed that this would
require follow-up of pregnancies and children resulting from the use of
this technology. Some participants thought that also psychosocial tests
should be included, but others thought that this would be not necessary,
as they did not believe there would be an effect on psychosocial well-
being.
For parents to allow children to be followed up after such procedure
was seen as a moral duty by the participants and a prerequisite to be
allowed to participate in such experimental procedure. This moral
duty was also there for professionals and for funding bodies: if research
to develop these techniques were to be funded, the follow-up should be
included from the beginning:
We are under a moral obligation to do a long-term follow-up. You also see it
in preterm birth, if you investigate premature children you see a small bar of
damage and challenges, but the longer you follow them up the more these
bars grow. (BE)
In this quote, the analogy with children created and/or born under other
technically new conditions was drawn, and the interviewee explicitly
points out the fact that potential damage may only become apparent
after quite some time. Interestingly, the potential of such unforeseen
damage was not quoted as a sufficient reason not to proceed with the
development of these techniques.
The fact that there would be potential transgenerational risks asso-
ciated with the procedure, which is basically germ-line modification,
was not deemed sufficient to disallow the technique altogether, and
interviewees stated that the decision-making authority of whether to
reproduce using techniques that may have transgenerational effects
should ultimately lie with the parents. One solution to the problem
that has been suggested in the literature is to allow for the selection of
only male embryos, as this would limit any potential risk to the first
generation born (Bredenoord et al., 2010). Some interviewees thought
this was an acceptable solution and it would fit within the definition of
sex selection for medical reasons. Others were more uncomfortable
with the suggestion, as this quote suggests:
I think it would be better to develop to design the technique in such a way that
you can have both boys and girls. It would be my preference to do that. So,
well, if you sayweare going to do boys and not girls, youhave a different story.
(NL)
So in this quote the interviewee suggests that developing a technique that
would only be safe if boys were chosen was still not a satisfactory solu-
tion. One interviewee suggested that sex selection could be deployed
until the technique was proven safe in the first generation, because she
believed that in that case, the transgenerational risk would have
decreased to an acceptable level.
Discussion
Although there seems to be a logical link between valuing the fact that
people can have their genetically own children and approving not only
of research aimed at developing mitochondrial replacement techniques,
but also eventually of reimbursement of assisted reproduction using this
technology, this seemed not to be so straightforward in the interviews.
On the one hand, interviewees thought this technique was worthy of
further exploration, and they acknowledged that people would go to
extremes to have a genetically own child. This is consistent with the find-
ings in the HFEA consultations where respondents were positive about
the new techniques, and related this to the fundamental right of parents
to pass on their own genes (HFEA, 2013). On the other hand, many of
our interviewees did not believe that to have a genetically own child,
although very important to most people, was a right or a sufficient
reason to develop and use experimental techniques. Indeed, in this
respect, it has been argued in the related debate about research invest-
ments aimed at developing stem cell-derived (‘artificial’) gametes for re-
productive use that alleviating the pain of infertile couples should always
be balanced against the risks involved for themselves and their future off-
spring and against other needs in society that may have a more convincing
claim on the healthcare budget (Dondorp and De Wert, 2012; Mertes,
2014). This mayalso apply to the technique of nuclear transfer. Indeed, as
Heidi Mertes argues, offering couples insight in the reasons why they
prefer genetic parenthood and subsequently discuss with them
whether theydo not overestimate the importance of genetic parenthood
may be a preliminary step before offering them techniques to achieve this
goal. Our interviewees thought that the fundamental scientific knowl-
edge and potential alternative applications that would be generated by
the development of these techniques, would still make it worthwhile
to pursue them. Hence, although the importance of a genetically
related child is the primary reason to invest in the development of this
technique, our study suggests that this may not be the only reason.
Whether it would be possible to provide a technique that would
sufficiently reduce transmission risks was the main moral concern of the
participants. They acknowledged that with techniques involving human
reproduction, such as this one, safety is never 100% guaranteed and that
an assessment of the risks can only be done after the first babies are
born and followed up for several years. Even then, there may be transge-
nerational risks. As a commentator stated: ‘The only way to find out about
safety is to license the first treatment’ (Poulton and Oakeshott, 2012).
Pre-clinical research using human embryos was deemed necessary to
eliminate harm further down the line as much as possible. As Provoost
et al. have argued, a framework distinguishing between experimental, in-
novative and established treatment could help to define milestones to
be reached and to decide when the technique is sufficiently proven and
safe enough to go to the next stage (Provoost et al., 2014). But intervie-
wees also agreed that long-term follow-up of the children was needed.
This is in agreement with the findings of the Nuffield Council of Bioethics
who stated that families using such techniques should commit to allowing
very long-term follow-up of their children and families (Nuffield Council on
Bioethics, 2012). It can be asked, however, how this relates to the right of
future children not to be burdened with research. Although this seems an
important proportionality-affecting question, the fact that these children,
who are already conceived in a nontraditional way, would be more
scrutinized and screened than their peers was not mentioned as ethically
problematic in our study.
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In the current debate on nuclear transfer it has been stated that the fact
that these techniques would affect the germ line complicates the matter
of follow-up even more. However, this was not seen by our participants
as a reason not to proceed with the development of the technique.
The right of parents to decide for themselves whether to change the
germ line was explicitly mentioned, which is analogous to what was
found in the HFEA consultation (HFEA, 2013). Although the fact that
sex selection to prevent the birth of girls from this technique has been
suggested as a technically feasible approach to avoid transgenerational
harm (Bredenoord et al., 2010), as mitochondria are transmitted from
a mother to her children, not all interviewees thought this was accept-
able. They believed that it should in principle be possible for parents to
have children of either sex. In this respect, participants also stated that
techniques should in principle be safe for anyone before being implemen-
ted, although sex selection could be a way to investigate safety further, to
avoid risks to be passed to the next generation in the first stages of
implementation.
Views on the nature of the contribution of the mtDNA influenced
interviewee’s opinions on both the acceptability of germ-line modifica-
tion and on the status of the mtDNA donor. The article in the Dutch
Embryos Act that forbids modification of the nuclear DNA is inspired
by the view that mitochondria are less linked with essential characteris-
tics of the individual than nuclear DNA. This view was shared by some of
our interviewees but not by others, who claimed that mtDNA may have
an important contribution in this respect as well. The latter viewpoint is
analogous with what Bredenoord et al. (2011) have argued about the
moral acceptability of germ-line modification for mitochondrial diseases.
They argue that this does not depend on whether the intervention alters
the identity of the future child or not, because it is not settled in science
whether the mtDNA may also be associated with essential characteris-
tics, and that the definition of what are essential characteristics for an in-
dividual is not precisely defined (Bredenoord et al., 2011; Roubertoux
et al., 2003). Indeed, one could state that having a pervasive mitochon-
drial disorder, such as MELAS, may in itself be seen as identity defining,
and that its effects on the germ line over several generations may be
more profound than some nuclear changes. Some suggest that what is
important in the discussion is whether this would eradicate disease
and offer the resulting children a life free of disease, and hence a more
open future. The idea that the acceptability of germ-line modification,
be it nuclear or mitochondrial, depends on whether or not it eliminates
disease, was also expressed by some of our interviewees.
Most interviewees rejected the three-parent label, as they considered
mitochondria of too limited importance to attribute to them some kind
of parental status. This is similar to what was found in the HFEA consult-
ation. However, the views of the respondents in the HFEA consultation
on the status of the mtDNA donor were shaped by the information on
the amount and the role of mtDNA. This is similar to our findings, where
interviewees who did not see the mtDNA as a trivial contribution to the
characteristics of an individual would also not consider the contribution
of the mtDNA donor as trivial. Hence, this suggests that views regarding
impact and acceptability of germ-line modification and the status of the
donor of the mitochondria may evolve as more becomes known about
the role of mtDNA.
Our study has many limitations. In translating the quotes from Dutch to
English some of the linguistic nuances may have been lost. We only inter-
viewed12 individuals in twocountries,whoseviewsshouldnotberegarded
as representative of the values and opinions that may be held by
professionals worldwide on this matter. Indeed, our study did not include
medical professionals with a strong view that there are ethical objections.
We had expected that by interviewing professionals both from Belgium
and the Netherlands, as these countries have distinct legal backgrounds
and traditions in embryo research, we would have found more opposing
views with regard to the ethical acceptability. Our sample is however too
small to draw any definite conclusions in this respect. To further explore
the issue at hand, a subsequent investigation of the opinions of people
affected by mitochondrial diseases and of the general public is necessary.
This study has shown that, although amongst the professionals we inter-
viewed there was support for the development and deployment of nuclear
transfer, this support does not necessarily correspond to uniform opinions
about the importance of having children of whom both parents are genetic
parents, or the contribution of mtDNA.
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